Skip to main content
. Author manuscript; available in PMC: 2015 Dec 20.
Published in final edited form as: FEBS Lett. 2014 Nov 21;588(24):4825–4830. doi: 10.1016/j.febslet.2014.11.017

Fig. 3. Scriptaid increases NOR1 promoter activity without affecting NOR1 transcript stability.

Fig. 3

Fig. 3

(A) RASMC were transiently transfected with a luciferase reporter construct (2 µg) driven by a 1.7kb NOR1 promoter fragment and stimulated with DMSO or Scriptaid (2 µg/ml) overnight. Protein lysate was collected and analyzed for luciferase activity. Data were normalized to Renilla luciferase activity and presented as mean ± SEM from three independently performed experiments (*P < 0.05 vs. 1 7 DMSO). (B) Quiescent RASMC (UT, untreated control) were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min and subsequently stimulated with PDGF (25 ng/ml) for 2 h. Actinomycin D (10 µg/ml) was added to inhibit transcription, and mRNA was collected at the indicated time points. NOR1 mRNA expression was normalized to RPL13A in three independent experiments. Data are expressed as mean ± SEM relative to samples stimulated with PDGF for 2 h without actinomycin. N.S. indicates that no statistical significance was detected between DMSO and Scriptaid treatments.